Monthly Archives: September 2015

Biopharmaceutical News Week 39

Acquisitions /mergers/joint-ventures   Aduro Biotech (Berkeley, CA, USA) acquires BioNovion (Oss, The Netherlands), a company dedicated to antibodies and checkpoint inhibitors for $32.5 million: about $16 million in cash and $16 million in stock as well as subsequent regulatory milestones.     Business   Regeneron Pharma will receive $17 million funding from US Department of Health […]

read more

Biopharmaceutical News Week 38

Editor’s Note   New drug approvals hit a record high in 2014 and one can expect a similar figure in 2015. Among these new approvals some will constitute real innovative breakthrough therapies but they often come at a very high cost. Several Institutes and Non-Profit organizations have published studies evaluating the evidence on the value […]

read more

Biopharmaceutical Newsletter Feedback

Dear Subscribers and dear Readers We are very pleased to inform you that the number of subscribers and of readers of our free of charge Biopharmaceutical Newsweek letter has steadily increased since the launch of the new version at the beginning of this year.  Some of you have already told us that they were highly […]

read more

Biopharmaceutical News Week 37

Acquisitions /mergers/joint-ventures   Mylan goes on with its hostile bid over Perrigo in a deal valued at $27 billion. Under the unveiled proposal, Perrigo stockholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, equating to about $187 a share overall. According to Perrigo’s management the offer remains under […]

read more

Biopharmaceutical News Week 36

Editor’s Note After a restful summer break, we are now back with business as usual with a full fletched version of our Biopharmaceutical NewsWeek. We have also received constructive comments following our short survey and we will consider them and hopefully improve our future weekly deliverable. We are starting with a very busy week already. […]

read more

Biopharmaceutical News Week 35

Acquisitions /mergers/joint-ventures   Novo Nordisk acquires Calibrium LLC and MB2 LLC, two privately-held biotechnology companies, to expand its reach in the diabetes and obesity field. Calibrium is focused on novel peptides and MB2 on first-in-class, mixed agonist drugs.  Financial details were not disclosed. Medtronic acquires Twelve, a medical device company for up to $458 million. The acquisition […]

read more